Justin Taylor1, Xiaoli Mi2, Alexander V Penson2, Stella V Paffenholz2, Kelsey Alvarez3, Allison Sigler4, Stephen S Chung3, Raajit K Rampal3, Jae H Park3, Eytan M Stein3, Martin S Tallman3, Filiz Sen4, Mithat Gönen5, Omar Abdel-Wahab6, Virginia M Klimek7. 1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 2. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: klimekv@mskcc.org.
Abstract
BACKGROUND: The median overall survival of patients with high-risk myelodysplastic syndromes refractory to hypomethylating agents is less than 6 months. Currently, no standard therapy for such patients exists. Preclinical studies have shown that inhibition of the nuclear export protein exportin 1 (XPO1) causes nuclear accumulation of p53 and disruption of NF-κB signalling, both relevant targets for myelodysplastic syndromes. We therefore aimed to assess the safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. METHODS: We did a single-centre, single-arm, phase 2 trial at the Memorial Sloan Kettering Cancer Center in the USA. We included patients 18 years or older with high-risk myelodysplastic syndromes or oligoblastic acute myeloid leukaemia (defined as blasts ≥20% but ≤30%) refractory to hypomethylating agents and with an Eastern Cooperative Oncology Group performance status score of 0-2. Eligible patients received 3-week long cycles of oral selinexor (60 mg twice per week for 2 weeks, followed by 1 week off). The primary outcome was overall response rate. Complete remission, partial remission, marrow complete remission, or haematological improvement were included in the response categories for assessing the primary endpoint. The activity analysis included all patients who completed at least one full-scheduled post-treatment disease assessment. All patients who were given selinexor were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT02228525. FINDINGS: Between Sept 23, 2014, and March 13, 2018, 25 patients were enrolled on this study. The median follow-up was 8·5 months (IQR 3·1-12·2). Two patients did not meet the full eligibility criteria after baseline assessment; therefore, 23 patients were evaluable for activity assessment. In the 23 evaluable patients, overall response rate was 26% (95% CI 10-48) in six patients with marrow complete remission, with an additional 12 patients (52%, 95% CI 31-73) achieving stable disease. The most common grade 3 or 4 adverse events were thrombocytopenia (eight [32%] of 25 patients) and hyponatraemia (five [20%]). There were no drug-related serious adverse events and no treatment-related deaths. INTERPRETATION: Selinexor showed responses in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. Adverse events were manageable with supportive care implementation. Further studies are needed to compare selinexor with supportive care alone, and to identify patient subgroups that might benefit the most from selinexor treatment. FUNDING: Karyopharm Therapeutics.
BACKGROUND: The median overall survival of patients with high-risk myelodysplastic syndromes refractory to hypomethylating agents is less than 6 months. Currently, no standard therapy for such patients exists. Preclinical studies have shown that inhibition of the nuclear export protein exportin 1 (XPO1) causes nuclear accumulation of p53 and disruption of NF-κB signalling, both relevant targets for myelodysplastic syndromes. We therefore aimed to assess the safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. METHODS: We did a single-centre, single-arm, phase 2 trial at the Memorial Sloan Kettering Cancer Center in the USA. We included patients 18 years or older with high-risk myelodysplastic syndromes or oligoblastic acute myeloid leukaemia (defined as blasts ≥20% but ≤30%) refractory to hypomethylating agents and with an Eastern Cooperative Oncology Group performance status score of 0-2. Eligible patients received 3-week long cycles of oral selinexor (60 mg twice per week for 2 weeks, followed by 1 week off). The primary outcome was overall response rate. Complete remission, partial remission, marrow complete remission, or haematological improvement were included in the response categories for assessing the primary endpoint. The activity analysis included all patients who completed at least one full-scheduled post-treatment disease assessment. All patients who were given selinexor were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT02228525. FINDINGS: Between Sept 23, 2014, and March 13, 2018, 25 patients were enrolled on this study. The median follow-up was 8·5 months (IQR 3·1-12·2). Two patients did not meet the full eligibility criteria after baseline assessment; therefore, 23 patients were evaluable for activity assessment. In the 23 evaluable patients, overall response rate was 26% (95% CI 10-48) in six patients with marrow complete remission, with an additional 12 patients (52%, 95% CI 31-73) achieving stable disease. The most common grade 3 or 4 adverse events were thrombocytopenia (eight [32%] of 25 patients) and hyponatraemia (five [20%]). There were no drug-related serious adverse events and no treatment-related deaths. INTERPRETATION: Selinexor showed responses in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents. Adverse events were manageable with supportive care implementation. Further studies are needed to compare selinexor with supportive care alone, and to identify patient subgroups that might benefit the most from selinexor treatment. FUNDING: Karyopharm Therapeutics.
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Christine Chen; David Siegel; Martin Gutierrez; Meagan Jacoby; Craig C Hofmeister; Nashat Gabrail; Rachid Baz; Morten Mau-Sorensen; Jesus G Berdeja; Michael Savona; Lynn Savoie; Suzanne Trudel; Nuchanan Areethamsirikul; T J Unger; Tami Rashal; Tim Hanke; Michael Kauffman; Sharon Shacham; Donna Reece Journal: Blood Date: 2017-12-04 Impact factor: 22.113
Authors: Ajai Chari; Dan T Vogl; Maria Gavriatopoulou; Ajay K Nooka; Andrew J Yee; Carol A Huff; Philippe Moreau; David Dingli; Craig Cole; Sagar Lonial; Meletios Dimopoulos; A Keith Stewart; Joshua Richter; Ravi Vij; Sascha Tuchman; Marc S Raab; Katja C Weisel; Michel Delforge; Robert F Cornell; David Kaminetzky; James E Hoffman; Luciano J Costa; Terri L Parker; Moshe Levy; Martin Schreder; Nathalie Meuleman; Laurent Frenzel; Mohamad Mohty; Sylvain Choquet; Gary Schiller; Raymond L Comenzo; Monika Engelhardt; Thomas Illmer; Philip Vlummens; Chantal Doyen; Thierry Facon; Lionel Karlin; Aurore Perrot; Klaus Podar; Michael G Kauffman; Sharon Shacham; Lingling Li; Shijie Tang; Carla Picklesimer; Jean-Richard Saint-Martin; Marsha Crochiere; Hua Chang; Samir Parekh; Yosef Landesman; Jatin Shah; Paul G Richardson; Sundar Jagannath Journal: N Engl J Med Date: 2019-08-22 Impact factor: 91.245
Authors: Dan T Vogl; David Dingli; Robert Frank Cornell; Carol Ann Huff; Sundar Jagannath; Divaya Bhutani; Jeffrey Zonder; Rachid Baz; Ajay Nooka; Joshua Richter; Craig Cole; Ravi Vij; Andrzej Jakubowiak; Rafat Abonour; Gary Schiller; Terri L Parker; Luciano J Costa; David Kaminetzky; James E Hoffman; Andrew J Yee; Ajai Chari; David Siegel; Rafael Fonseca; Scott Van Wier; Gregory Ahmann; Ilsel Lopez; Michael Kauffman; Sharon Shacham; Jean-Richard Saint-Martin; Carla D Picklesimer; Cassandra Choe-Juliak; A Keith Stewart Journal: J Clin Oncol Date: 2018-01-30 Impact factor: 44.544
Authors: Molly A Smith; Gaurav S Choudhary; Andrea Pellagatti; Kwangmin Choi; Lyndsey C Bolanos; Tushar D Bhagat; Shanisha Gordon-Mitchell; Dagny Von Ahrens; Kith Pradhan; Violetta Steeples; Sanghyun Kim; Ulrich Steidl; Matthew Walter; Iain D C Fraser; Aishwarya Kulkarni; Nathan Salomonis; Kakajan Komurov; Jacqueline Boultwood; Amit Verma; Daniel T Starczynowski Journal: Nat Cell Biol Date: 2019-04-22 Impact factor: 28.824
Authors: Stanley Chun-Wei Lee; Heidi Dvinge; Eunhee Kim; Hana Cho; Jean-Baptiste Micol; Young Rock Chung; Benjamin H Durham; Akihide Yoshimi; Young Joon Kim; Michael Thomas; Camille Lobry; Chun-Wei Chen; Alessandro Pastore; Justin Taylor; Xujun Wang; Andrei Krivtsov; Scott A Armstrong; James Palacino; Silvia Buonamici; Peter G Smith; Robert K Bradley; Omar Abdel-Wahab Journal: Nat Med Date: 2016-05-02 Impact factor: 53.440